{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T02:06:21Z","timestamp":1785549981756,"version":"3.56.0"},"reference-count":20,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,7,30]]},"DOI":"10.7759\/cureus.89091","type":"journal-article","created":{"date-parts":[[2025,7,31]],"date-time":"2025-07-31T04:21:38Z","timestamp":1753935698000},"source":"Crossref","is-referenced-by-count":3,"title":["Effects of Dapagliflozin vs. Vildagliptin on the Lipid Profile of Patients With Uncontrolled Type 2 Diabetes"],"prefix":"10.7759","author":[{"given":"Shreshth","family":"Khanna","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mayank","family":"Malik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Razi","family":"Ahmad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","article-title":"Global, regional, and national burden of diabetes from 1990 to 2021, with projections of prevalence to 2050: a systematic analysis for the Global Burden of Disease Study 2021","volume":"402","year":"2021","unstructured":"Global, regional, and national burden of diabetes from 1990 to 2021, with projections of prevalence to 2050. a systematic analysis for the Global Burden of Disease Study 2021. Lancet. 2021, 402:203-34.","journal-title":"Lancet"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1038\/nrendo.2017.151","article-title":"Global aetiology and epidemiology of type 2 diabetes mellitus and its complications","volume":"14","author":"Zheng Y","year":"2018","unstructured":"Zheng Y, Ley SH, Hu FB. Global aetiology and epidemiology of type 2 diabetes mellitus and its complications. Nat Rev Endocrinol. 2018, 14:88-98. 10.1038\/nrendo.2017.151","journal-title":"Nat Rev Endocrinol"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.25259\/IJPP_257_2022","article-title":"Efficacy and safety of saroglitazar and fenofibrate in the treatment of diabetic dyslipidaemia: a pilot study","volume":"67","author":"Gahlot R","year":"2023","unstructured":"Gahlot R, Kumar S, Garg S. Efficacy and safety of saroglitazar and fenofibrate in the treatment of diabetic dyslipidaemia: a pilot study. Indian J Physiol Pharmacol. 2023, 67:15-20. 10.25259\/IJPP_257_2022","journal-title":"Indian J Physiol Pharmacol"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1016\/j.metabol.2022.155142","article-title":"Insulin: the master regulator of glucose metabolism","volume":"129","author":"Norton L","year":"2022","unstructured":"Norton L, Shannon C, Gastaldelli A, DeFronzo RA. Insulin: the master regulator of glucose metabolism. Metabolism. 2022, 129:10.1016\/j.metabol.2022.155142","journal-title":"Metabolism"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2023.1149239","article-title":"The crucial role and mechanism of insulin resistance in metabolic disease","volume":"14","author":"Zhao X","year":"2023","unstructured":"Zhao X, An X, Yang C, Sun W, Ji H, Lian F. The crucial role and mechanism of insulin resistance in metabolic disease. Front Endocrinol (Lausanne). 2023, 14:10.3389\/fendo.2023.1149239","journal-title":"Front Endocrinol (Lausanne)"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.2147\/DMSO.S317659","article-title":"A comparison between the therapeutic effect of metformin alone versus a combination therapy with insulin in uncontrolled, non-adherence patients with type 2 diabetes: six months follow-up","volume":"14","author":"Paczkowska A","year":"2021","unstructured":"Paczkowska A, Hoffmann K, Michalak M, et al.. A comparison between the therapeutic effect of metformin alone versus a combination therapy with insulin in uncontrolled, non-adherence patients with type 2 diabetes: six months follow-up. Diabetes Metab Syndr Obes. 2021, 14:3243-52. 10.2147\/DMSO.S317659","journal-title":"Diabetes Metab Syndr Obes"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2019.00389","article-title":"Clinical use of DPP-4 inhibitors","volume":"10","author":"Gallwitz B","year":"2019","unstructured":"Gallwitz B. Clinical use of DPP-4 inhibitors. Front Endocrinol (Lausanne). 2019, 10:10.3389\/fendo.2019.00389","journal-title":"Front Endocrinol (Lausanne)"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.2147\/DMSO.S212003","article-title":"Sodium-glucose cotransporter-2 (SGLT2) inhibitors: a clinician's guide","volume":"12","author":"Simes BC","year":"2019","unstructured":"Simes BC, MacGregor GG. Sodium-glucose cotransporter-2 (SGLT2) inhibitors: a clinician's guide. Diabetes Metab Syndr Obes. 2019, 12:2125-36. 10.2147\/DMSO.S212003","journal-title":"Diabetes Metab Syndr Obes"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.3390\/ijerph16152720","article-title":"The role of DPP-4 inhibitors in the treatment algorithm of type 2 diabetes mellitus: when to select, what to expect","volume":"16","author":"Makrilakis K","year":"2019","unstructured":"Makrilakis K. The role of DPP-4 inhibitors in the treatment algorithm of type 2 diabetes mellitus: when to select, what to expect. Int J Environ Res Public Health. 2019, 16:10.3390\/ijerph16152720","journal-title":"Int J Environ Res Public Health"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1177\/1074248418817345","article-title":"The role of vildagliptin in treating hypertension through modulating serum VEGF in diabetic hypertensive patients","volume":"24","author":"El-Naggar AR","year":"2019","unstructured":"El-Naggar AR, Zaafar D, Elyamany M, Hassanin S, Bassyouni A, Abdel-Latif H. The role of vildagliptin in treating hypertension through modulating serum VEGF in diabetic hypertensive patients. J Cardiovasc Pharmacol Ther. 2019, 24:254-61. 10.1177\/1074248418817345","journal-title":"J Cardiovasc Pharmacol Ther"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.18637\/jss.v058.s01","article-title":"Statistical Software (R, SAS, SPSS, and Minitab) for blind students and practitioners","volume":"58","author":"Jonathan A","year":"2014","unstructured":"Jonathan A, Godfrey R, Loots MT. Statistical Software (R, SAS, SPSS, and Minitab) for blind students and practitioners. J Stat Softw. 2014, 58:10.18637\/jss.v058.s01","journal-title":"J Stat Softw"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1016\/j.eprac.2025.03.011","article-title":"Diabetes and lipids: a review and update on lipid biomarkers and cardiovascular risk","volume":"31","author":"Tsushima Y","year":"2025","unstructured":"Tsushima Y, Hatipoglu B. Diabetes and lipids: a review and update on lipid biomarkers and cardiovascular risk. Endocr Pract. 2025, 31:677-85. 10.1016\/j.eprac.2025.03.011","journal-title":"Endocr Pract"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1111\/dom.13258","article-title":"Safety and tolerability of dapagliflozin, saxagliptin and metformin in combination: post-hoc analysis of concomitant add-on versus sequential add-on to metformin and of triple versus dual therapy with metformin","volume":"20","author":"Del Prato S","year":"2018","unstructured":"Del Prato S, Rosenstock J, Garcia-Sanchez R, et al.. Safety and tolerability of dapagliflozin, saxagliptin and metformin in combination: post-hoc analysis of concomitant add-on versus sequential add-on to metformin and of triple versus dual therapy with metformin. Diabetes Obes Metab. 2018, 20:1542-6. 10.1111\/dom.13258","journal-title":"Diabetes Obes Metab"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.3389\/fcvm.2021.648212","article-title":"The association between metformin treatment and outcomes in type 2 diabetes mellitus patients with heart failure with preserved ejection fraction: a retrospective study","volume":"8","author":"Wang J","year":"2021","unstructured":"Wang J, Lu Y, Min X, Yuan T, Wei J, Cai Z. The association between metformin treatment and outcomes in type 2 diabetes mellitus patients with heart failure with preserved ejection fraction: a retrospective study. Front Cardiovasc Med. 2021, 8:10.3389\/fcvm.2021.648212","journal-title":"Front Cardiovasc Med"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.4103\/ijem.ijem_276_21","article-title":"Comparison of safety and efficacy of glimepiride-metformin and vildagliptin- metformin treatment in newly diagnosed type 2 diabetic patients","volume":"25","author":"Kumar S","year":"2021","unstructured":"Kumar S. Comparison of safety and efficacy of glimepiride-metformin and vildagliptin- metformin treatment in newly diagnosed type 2 diabetic patients. Indian J Endocrinol Metab. 2021, 25:326-31. 10.4103\/ijem.ijem_276_21","journal-title":"Indian J Endocrinol Metab"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1016\/j.diabres.2006.12.009","article-title":"Efficacy and tolerability of vildagliptin monotherapy in drug-na\u00efve patients with type 2 diabetes","volume":"76","author":"Pi-Sunyer FX","year":"2007","unstructured":"Pi-Sunyer FX, Schweizer A, Mills D, Dejager S. Efficacy and tolerability of vildagliptin monotherapy in drug-na\u00efve patients with type 2 diabetes. Diabetes Res Clin Pract. 2007, 76:132-8. 10.1016\/j.diabres.2006.12.009","journal-title":"Diabetes Res Clin Pract"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacl.2017.01.018","article-title":"Dapagliflozin in patients with type II diabetes mellitus, with and without elevated triglyceride and reduced high-density lipoprotein cholesterol levels","volume":"11","author":"Bays HE","year":"2017","unstructured":"Bays HE, Sartipy P, Xu J, Sj\u00f6str\u00f6m CD, Underberg JA. Dapagliflozin in patients with type II diabetes mellitus, with and without elevated triglyceride and reduced high-density lipoprotein cholesterol levels. J Clin Lipidol. 2017, 11:450-8. 10.1016\/j.jacl.2017.01.018","journal-title":"J Clin Lipidol"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1016\/j.phrs.2020.105068","article-title":"Effect of sodium-glucose co-transporter 2 inhibitors on lipid profile: a systematic review and meta-analysis of 48 randomized controlled trials","volume":"160","author":"S\u00e1nchez-Garc\u00eda A","year":"2020","unstructured":"S\u00e1nchez-Garc\u00eda A, Simental-Mend\u00eda M, Mill\u00e1n-Alan\u00eds JM, Simental-Mend\u00eda LE. Effect of sodium-glucose co-transporter 2 inhibitors on lipid profile: a systematic review and meta-analysis of 48 randomized controlled trials. Pharmacol Res. 2020, 160:10.1016\/j.phrs.2020.105068","journal-title":"Pharmacol Res"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1186\/s13098-023-01092-z","article-title":"Efficacy and safety evaluation of SGLT2i on blood pressure control in patients with type 2 diabetes and hypertension: a new meta-analysis","volume":"15","author":"Zhang Q","year":"2023","unstructured":"Zhang Q, Zhou S, Liu L. Efficacy and safety evaluation of SGLT2i on blood pressure control in patients with type 2 diabetes and hypertension: a new meta-analysis. Diabetol Metab Syndr. 2023, 15:10.1186\/s13098-023-01092-z","journal-title":"Diabetol Metab Syndr"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1002\/jcph.6105","article-title":"Influence of dapagliflozin dosing on low-density lipoprotein cholesterol in type 2 diabetes mellitus: a systematic literature review and meta-analysis","volume":"64","author":"Martha S","year":"2024","unstructured":"Martha S, Jangam PH, Bhansali SG. Influence of dapagliflozin dosing on low-density lipoprotein cholesterol in type 2 diabetes mellitus: a systematic literature review and meta-analysis. J Clin Pharmacol. 2024, 64:1528-40. 10.1002\/jcph.6105","journal-title":"J Clin Pharmacol"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/384177-effects-of-dapagliflozin-vs-vildagliptin-on-the-lipid-profile-of-patients-with-uncontrolled-type-2-diabetes","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,31]],"date-time":"2025-07-31T04:21:40Z","timestamp":1753935700000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/384177-effects-of-dapagliflozin-vs-vildagliptin-on-the-lipid-profile-of-patients-with-uncontrolled-type-2-diabetes"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,30]]},"references-count":20,"URL":"https:\/\/doi.org\/10.7759\/cureus.89091","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2025,7,30]]}}}